17 research outputs found

    Non-Dutch Petitions in the Seventeenth-Century Dutch Atlantic

    Get PDF
    This article argues for the centrality of petitions for colonial administration in the Dutch Atlantic. Moreover, through a study of non-Dutch petitioners, it demonstrates the diversity of individuals that exercised influence on colonial decision-making. This adds an important understanding of political exchanges to the well-established understanding of the Atlantic world as based on inter-imperial, cross-cultural, and multi-ethnic economic exchanges. The colonial inhabitants did not stand idly by as decisions in and from the European metropole or West India Company (WIC) administrators invaded their lives, but instead actively attempted to influence the rules and regulations that governed them. The space that allowed for this on-the-spot negotiation between the colonial government and those individuals it governed was open to virtually everybody and the topics covered were equally as varied, ranging from local decentralized authority to regulations for colonial commodities and issues of religion

    Serving the chain?: De Nederlandsche Bank and the last decades of slavery, 1814-1863

    Get PDF
    In the nineteenth century, when the principal cultural, political, and financial institutions of the Netherlands were established, slavery was still very much part of the nation’s global imperial structures. Dutch families, institutions, and governments are increasingly interested in the role their predecessors played in this history of colonialism and enslavement. This book is a history of De Nederlandse Bank in which particular attention is paid to its links with slavery, both as a factor in the economy and as a subject of political debate. Because De Nederlandse Bank served the Dutch Ministry of Colonies and consequently followed Dutch trade interests, the bank’s history intersects with the history of slavery. The investigation in this book focuses not only on the DNB’s formal involvement but also on the private involvement of its directors. In addition, it examines whether the bank and its directors played any role in the abolition of slavery.With the cooperation of Zipphora Dors, Leonoor Kemperman, Camilla de Koning and Sakina Mouam

    Resectability and Ablatability Criteria for the Treatment of Liver Only Colorectal Metastases:Multidisciplinary Consensus Document from the COLLISION Trial Group

    Get PDF
    The guidelines for metastatic colorectal cancer crudely state that the best local treatment should be selected from a 'toolbox' of techniques according to patient- and treatment-related factors. We created an interdisciplinary, consensus-based algorithm with specific resectability and ablatability criteria for the treatment of colorectal liver metastases (CRLM). To pursue consensus, members of the multidisciplinary COLLISION and COLDFIRE trial expert panel employed the RAND appropriateness method (RAM). Statements regarding patient, disease, tumor and treatment characteristics were categorized as appropriate, equipoise or inappropriate. Patients with ECOG≤2, ASA≤3 and Charlson comorbidity index ≤8 should be considered fit for curative-intent local therapy. When easily resectable and/or ablatable (stage IVa), (neo)adjuvant systemic therapy is not indicated. When requiring major hepatectomy (stage IVb), neo-adjuvant systemic therapy is appropriate for early metachronous disease and to reduce procedural risk. To downstage patients (stage IVc), downsizing induction systemic therapy and/or future remnant augmentation is advised. Disease can only be deemed permanently unsuitable for local therapy if downstaging failed (stage IVd). Liver resection remains the gold standard. Thermal ablation is reserved for unresectable CRLM, deep-seated resectable CRLM and can be considered when patients are in poor health. Irreversible electroporation and stereotactic body radiotherapy can be considered for unresectable perihilar and perivascular CRLM 0-5cm. This consensus document provides per-patient and per-tumor resectability and ablatability criteria for the treatment of CRLM. These criteria are intended to aid tumor board discussions, improve consistency when designing prospective trials and advance intersociety communications. Areas where consensus is lacking warrant future comparative studies.</p

    Colorectal liver metastases: Surgery versus thermal ablation (COLLISION) - a phase III single-blind prospective randomized controlled trial

    Get PDF
    Background: Radiofrequency ablation (RFA) and microwave ablation (MWA) are widely accepted techniques to eliminate small unresectable colorectal liver metastases (CRLM). Although previous studies labelled thermal ablation inferior to surgical resection, the apparent selection bias when comparing patients with unresectable disease to surgical candidates, the superior safety profile, and the competitive overall survival results for the more recent reports mandate the setup of a randomized controlled trial. The objective of the COLLISION trial is to prove non-inferiority of thermal ablation compared to hepatic resection in patients with at least one resectable and ablatable CRLM and no extrahepatic disease. Methods: In this two-arm, single-blind multi-center phase-III clinical trial, six hundred and eighteen patients with at least one CRLM (≤3cm) will be included to undergo either surgical resection or thermal ablation of appointed target lesion(s) (≤3cm). Primary endpoint is OS (overall survival, intention-to-treat analysis). Main secondary endpoints are overall disease-free survival (DFS), time to progression (TTP), time to local progression (TTLP), primary and assisted technique efficacy (PTE, ATE), procedural morbidity and mortality, length of hospital stay, assessment of pain and quality of life (QoL), cost-effectiveness ratio (ICER) and quality-adjusted life years (QALY). Discussion: If thermal ablation proves to be non-inferior in treating lesions ≤3cm, a switch in treatment-method may lead to a reduction of the post-procedural morbidity and mortality, length of hospital stay and incremental costs without compromising oncological outcome for patients with CRLM. Trial registration:NCT03088150 , January 11th 2017
    corecore